ES2235896T3 - Uso de riluzol para el tratamaiento de la esclerosis multiple. - Google Patents

Uso de riluzol para el tratamaiento de la esclerosis multiple.

Info

Publication number
ES2235896T3
ES2235896T3 ES00939007T ES00939007T ES2235896T3 ES 2235896 T3 ES2235896 T3 ES 2235896T3 ES 00939007 T ES00939007 T ES 00939007T ES 00939007 T ES00939007 T ES 00939007T ES 2235896 T3 ES2235896 T3 ES 2235896T3
Authority
ES
Spain
Prior art keywords
treatment
riluzole
multiple sclerosis
interferon
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00939007T
Other languages
English (en)
Spanish (es)
Inventor
Chris Polman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Amsterdam
Original Assignee
Vrije Universiteit Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Amsterdam filed Critical Vrije Universiteit Amsterdam
Application granted granted Critical
Publication of ES2235896T3 publication Critical patent/ES2235896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES00939007T 1999-06-04 2000-06-02 Uso de riluzol para el tratamaiento de la esclerosis multiple. Expired - Lifetime ES2235896T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
US174328P 2000-01-04

Publications (1)

Publication Number Publication Date
ES2235896T3 true ES2235896T3 (es) 2005-07-16

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00939007T Expired - Lifetime ES2235896T3 (es) 1999-06-04 2000-06-02 Uso de riluzol para el tratamaiento de la esclerosis multiple.

Country Status (11)

Country Link
EP (2) EP1187612B1 (https=)
JP (1) JP2003522121A (https=)
AT (2) ATE419851T1 (https=)
AU (1) AU777537B2 (https=)
CA (1) CA2375874A1 (https=)
DE (1) DE60017733T2 (https=)
ES (1) ES2235896T3 (https=)
NZ (1) NZ515685A (https=)
PT (1) PT1187612E (https=)
SI (1) SI1187612T1 (https=)
WO (1) WO2000074676A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
AU2005218625A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
MX2017006454A (es) * 2014-11-21 2018-03-23 Biohaven Pharm Holding Co Ltd Administracion sublingual de riluzol.
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
US6133258A (en) * 1995-11-05 2000-10-17 Yamanouchi Pharmaceutical Co., Ltd. Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
ATE419851T1 (de) 2009-01-15
JP2003522121A (ja) 2003-07-22
ATE287713T1 (de) 2005-02-15
WO2000074676A1 (en) 2000-12-14
EP1187612B1 (en) 2005-01-26
PT1187612E (pt) 2005-05-31
AU5421900A (en) 2000-12-28
EP1552831B1 (en) 2009-01-07
DE60017733D1 (de) 2005-03-03
SI1187612T1 (en) 2005-06-30
EP1552831A1 (en) 2005-07-13
EP1187612A1 (en) 2002-03-20
NZ515685A (en) 2002-12-20
CA2375874A1 (en) 2000-12-14
AU777537B2 (en) 2004-10-21
DE60017733T2 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
US20080214631A1 (en) Use of riluzole for the treatment of multiple sclerosis
US20110046119A1 (en) Therapeutic treatment
ES2235896T3 (es) Uso de riluzol para el tratamaiento de la esclerosis multiple.
WO2008073779A2 (en) Compositions and methods for treating seizures
US20230089715A1 (en) Masitinib for the treatment of a multiple sclerosis patient subpopulation
CZ285633B6 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
ES2199339T3 (es) Analogos de nucleosidos en la terapia combinada de infecciones por herpes simplex.
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
US5162375A (en) Treatment of neuronal degeneration with 5HT1A agonists
CA2568436A1 (en) Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
US20120058121A1 (en) Methods and compositions for treating lupus
AU2008201290B2 (en) Therapeutic treatment
HK1076049B (en) Use of riluzole for treating multiple sclerosis
CA2274858A1 (en) Novel treatment
ES2363931T3 (es) Agente reparador para enfermedad glumerular.
AU7860394A (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
JPS5920221A (ja) レイノ−症状の改善・治療剤
HK40060509A (en) Combination comprising sildenafil for use in the treatment of osteoarthritis
HK1141724A1 (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
HK1090553B (en) A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis